Ovarian Carcinoma Metastasis to the Breast Case Report and Review of the Literature

Yamasaki, Hiroshi; Saw, Daisy; Zdanowitz, Joel; Faltz, L.

doi:10.1097/00000478-199302000-00011

Cited by 47 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in our series, the most commonly reported gynecologic cancer to metastasize to the breast is serous carcinoma. [7][8][9] Other unusual gynecologic tumors reported to have metastasized to the breast included endometrial stromal sarcoma, 14 ovarian clear cell carcinoma, 7 ovarian granulosa cell tumor 15 ovarian dysgerminoma 16 and choriocarcinoma. 5 The current study included one ovarian clear cell carcinoma and one choriocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

“…2,5,30,32 The exception to this is serous ovarian carcinoma, which very frequently has psammomatous calcifications. 8,9 These features contrast with primary breast carcinoma, as it is usually an ill-defined lesion, infiltrates breast parenchyma, and often contains in situ carcinoma and calcifications (non-psammomatous). While most studies have found similar results, in the series by Lee et al, 4 calcifications were identified in one hepatocellular carcinoma and two gastric carcinomas metastatic to the breast.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-mammary metastases to the breast and axilla: a study of 85 cases

et al. 2013

View full text Add to dashboard Cite

Non-mammary metastases to the breast and axilla are rare occurrences. However, they are important diagnostic considerations as their treatment and prognosis differ significantly from primary breast cancer. Between 1990 and 2010, we identified a total of 85 patients, 72 women and 13 men, with non-mammary malignancies involving the breast, axilla, or both. The tumor types consisted of carcinoma (58%), melanoma (22%) and sarcoma (20%). Ovary was the most common site of origin for carcinoma, and metastatic high-grade ovarian serous carcinoma was most frequently misdiagnosed as a primary breast carcinoma. Melanoma was the single most common non-carcinomatous tumor type to involve the breast and/or axilla, and uterine leiomyosarcoma was the most common type of sarcoma. Most patients (77%) had other metastases at the time of diagnosis of the tumor, but in 11% the breast or axillary lesion was the first presentation. Without a clinical history, non-mammary metastases were difficult to diagnose because the majority of cases presented with a solitary nodule and lacked pathognomonic pathologic features. There were, however, certain recurrent histological findings identified, such as the often relatively well-circumscribed growth pattern of the metastatic lesion surrounded by a fibrous pseudocapsule, and the absence of an in situ carcinoma. Overall, these patients had poor survival; 96% of patients with follow-up available are dead of disease, with a median survival of 15 months after the diagnosis of the breast or axillary lesion. This finding emphasizes the need to accurately identify these tumors as metastases in order to avoid unnecessary procedures and treatments in these patients. Keywords: axilla; breast; extramammary Metastases to the breast and axilla are rare and account for approximately 2% of all mammary malignancies. 1,2 The most common metastatic lesion to involve the breast is a metastasis from a contralateral mammary cancer. 1,2 If hematologic malignancies are also excluded, the number of non-mammary metastases drops to well below 1%. 1,3 Owing to the frequency of primary breast cancers and the rarity of non-mammary tumors involving the breast, a newly discovered lesion in the breast or axilla is usually presumed to be a primary or metastatic breast carcinoma. However, the recognition of non-mammary metastases to the breast and axilla is very important, as both the treatment and prognosis differ significantly. Materials and methodsAfter obtaining approval by our Institutional Review Board, we searched the pathology database of Memorial Sloan-Kettering Cancer Center between the years 1990-2010 for patients with non-mammary metastases to the breast and axilla. Hematologic malignancies were excluded, as they are systemic diseases. The medical records and pathology slides, when available, were reviewed and the clinicopathologic characteristics were recorded. Patient age, gender, primary tumor site, the presence of other metastases, laterality, number of lesions, interval from primary tumor diagnosis to breast/ a...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Non-mammary metastases to the breast and axilla: a study of 85 cases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…In such cases tumoral markers (OC125, OV632 and placental alkaline phosphatase) and immunohistochemical staining can be useful to identify the site of origin of tumors with high sensitivity (0.86) and specificity (0.89) [2]. It is also interesting to note that in most reported cases multiple other sites of metastatic disease were apparent at the time of the diagnosis of breast involvement [2,4,5,10] whereas in our patient the breast was the only site of distant disease.…”

Section: Case Reportmentioning

confidence: 54%

“…Ovarian metastasis from primary breast carcinoma are quite frequent, representing 3-10% of all malignancies of the ovary and 24-39% of the metastatic disease [1]. On the other hand, breast metastasis of ovarian carcinoma is extremely uncommon [2][3][4][5]. Generally the breast is not considered a common site of metastatic disease from solid tumors.…”

Section: Introductionmentioning

confidence: 99%

Ovarian Carcinoma Metastatic to the Breast

Cormio¹,

Vagno²,

Melilli³

et al. 2001

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Breast and ovarian tumors can be diffi cult to pathologically distinguish due to overlapping morphology (9), and immunohistochemistry may be required to distinguish the two. Estrogen and progesterone receptor expression are inadequate markers, as these can be seen in both breast and ovarian neoplasms.…”

Section: Unusual Presentation Of Metastatic Ovarian Carcinoma As An Ementioning

confidence: 99%